Compare IH & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IH | MXCT |
|---|---|---|
| Founded | 1996 | 1999 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.8M | 93.0M |
| IPO Year | 2020 | 2021 |
| Metric | IH | MXCT |
|---|---|---|
| Price | $1.68 | $0.81 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 8.4K | ★ 559.4K |
| Earning Date | 03-31-2026 | 05-12-2026 |
| Dividend Yield | ★ 5.88% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $33,026,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $18.50 |
| P/E Ratio | $7.30 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.55 | $0.64 |
| 52 Week High | $3.60 | $2.40 |
| Indicator | IH | MXCT |
|---|---|---|
| Relative Strength Index (RSI) | 44.86 | 46.61 |
| Support Level | $1.55 | $0.77 |
| Resistance Level | $1.83 | $0.89 |
| Average True Range (ATR) | 0.08 | 0.05 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 21.43 | 21.75 |
iHuman Inc is a Chinese company that uses artificial intelligence to create technology-driven puzzle products for children, making parenting easier and children happier. The company offers a range of intellectual development products that are designed to make the child-rearing experience more manageable for parents while turning intellectual development into a fun journey for children. Its revenue is generated from subscription fees paid by users for premium content on their self-directed and interactive online applications, as well as offline products and other sources.
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.